00000nam 2200000zi 4500 9.919396 CaOODSP 20230302165704 m o d f cr mn||||||||| 230124e202302##oncd ob f000 0 eng d 9780660472331 CaOODSP eng rda CaOODSP n-cn--- HP5-154/2023E-PDF Recommendations on the use of conjugate pneumococcal vaccine - 15 valent (PNEU-C-15) and 20 valent (PNEU-C-20) in adults : economic evidence supplementary appendix. Ottawa, ON : Public Health Agency of Canada = Agence de la santé publique du Canada, February 2023. ©2023 1 online resource (44 pages) : graphs text txt rdacontent computer c rdamedia online resource cr rdacarrier Issued also in French under title: Recommandations sur l'utilisation du vaccin conjugué 15-valent (PNEU-C-15) contre le pneumocoque et 20-valent (PNEU-C-20) contre le pneumocoque chez les adultes : annexe de données économiques supplémentaires. On cover: An advisory committee statement (ACS), National Advisory Committee on Immunization (NACI). "Pub.: 220714." Includes bibliographical references (pages 38-44). Pneumococcal vaccine Canada. Vaccines Economic aspects Canada. Public Health Agency of Canada, issuing body. Canada. National Advisory Committee on Immunization, issuing body. Recommandations sur l'utilisation du vaccin conjugué 15-valent (PNEU-C-15) contre le pneumocoque et 20-valent (PNEU-C-20) contre le pneumocoque chez les adultes : (CaOODSP)9.919397 PDF 1.87 MB https://publications.gc.ca/collections/collection_2023/aspc-phac/HP5-154-2023-eng.pdf HTML N/A https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/public-health-level-recommendations-use-pneumococcal-vaccines-adults-including-use-15-valent-20-valent-conjugate-vaccines/economic-evidence-supplementary-appendix.html